Lopinavir (ABT-378): Potent HIV Protease Inhibitor for Antiviral Research

Executive Summary: Lopinavir inhibits HIV protease at picomolar concentrations (K_i = 1.3–3.6 pM) in both wild-type and mutant strains, outperforming ritonavir in serum-rich environments due to its 10-fold higher potency (APExBIO product sheet; Lopinavir). Co-administration with ritonavir increases Lopinavir’s plasma AUC 14-fold in animal models (APExBIO). Lopinavir is also active against MERS-CoV in cell culture (EC₅₀ = 3–8 μM) (de Wilde et al., 2014). The compound's nanomolar efficacy and resistance profile make it a standard for HIV protease inhibition assays (ProteaseInhibitorLibrary). For optimal results, solutions should be freshly prepared and stored at -20°C (APExBIO).

Biological Rationale

HIV protease is essential for the maturation of infectious HIV particles. Inhibiting this enzyme halts viral replication and prevents the formation of mature, infectious virions (Ruxolitinib.us). Lopinavir (ABT-378) was rationally designed as a structural analog of ritonavir, with reduced interaction at the Val82 residue of HIV protease. This design minimizes resistance and maintains efficacy against strains selected under ritonavir pressure (ProteaseInhibitorLibrary). The HIV protease enzymatic pathway remains a validated target for antiretroviral therapy development, and Lopinavir's robust inhibition supports its use in research and clinical settings.

Mechanism of Action of Lopinavir

Lopinavir is a competitive inhibitor that binds to the active site of HIV-1 protease, preventing the cleavage of Gag-Pol polyproteins required for viral assembly (NCBI Bookshelf). The molecule’s high affinity (K_i = 1.3–3.6 pM) results in potent inhibition under physiological conditions. Structural modifications relative to ritonavir reduce susceptibility to resistance mutations, notably at Val82, and confer activity against both wild-type and multiple resistant HIV-1 proteases. Lopinavir’s antiviral effect is not significantly diminished by human serum proteins, a key advantage over earlier protease inhibitors (Ruxolitinib.us). In cell-based assays, Lopinavir exhibits EC₅₀ values below 0.06 μM for wild-type and mutant strains, confirming its nanomolar efficacy.

Evidence & Benchmarks

• Lopinavir inhibits HIV-1 protease with K_i values of 1.3–3.6 pM (APExBIO, product page).
• Shows EC₅₀ < 0.06 μM against wild-type and Val82 mutant HIV strains in cell-based assays (ProteaseInhibitorLibrary).
• Demonstrates 10-fold greater potency than ritonavir in human serum (Ruxolitinib.us).
• In animal models, oral dosing (10 mg/kg) achieves C_max = 0.8 μg/mL, 25% bioavailability, and plasma levels fall below quantitation by 6 hours (APExBIO).
• Co-administration with ritonavir increases Lopinavir plasma AUC by 14-fold (APExBIO).
• Lopinavir is active against MERS-CoV in vitro (EC₅₀ 3–8 μM) (de Wilde et al., 2014).
• Stable in DMSO (≥31.45 mg/mL) and ethanol (≥48.3 mg/mL); insoluble in water (APExBIO).
• Retains efficacy in HIV strains with multiple resistance mutations (BMS-509744.com).

This article extends previous summaries such as this overview by providing updated quantitative benchmarks for serum activity and resistance, and by incorporating cross-pathogen antiviral data (e.g., MERS-CoV).

Applications, Limits & Misconceptions

Lopinavir is widely used in HIV protease inhibition assays, resistance profiling, and antiretroviral therapy development. Its robust activity profile makes it a tool of choice for benchmarking new inhibitors and assessing cross-resistance in laboratory settings (BMS-833923.com). APExBIO supplies Lopinavir (A8204) for research applications, where its defined potency and pharmacokinetics support reproducible results.

Common Pitfalls or Misconceptions

• Lopinavir is insoluble in water; improper solvent use leads to precipitation and loss of activity (APExBIO datasheet).
• Antiviral efficacy in vitro does not guarantee clinical effectiveness against non-HIV viruses (e.g., MERS-CoV); animal and human data are required (de Wilde et al., 2014).
• Serum proteins affect many protease inhibitors, but Lopinavir’s activity is relatively resistant; however, this does not eliminate all in vivo pharmacokinetic variability.
• Lopinavir is not a first-line monotherapy; it is typically co-formulated or co-administered with ritonavir to enhance plasma exposure (APExBIO).
• Solutions must be freshly prepared and stored at -20°C for short-term use; degradation can occur at room temperature (APExBIO).

Workflow Integration & Parameters

For HIV protease inhibition assays, Lopinavir is used at nanomolar concentrations (4–52 nM) in cell-based formats. Dissolution should be in DMSO (≥31.45 mg/mL) or ethanol (≥48.3 mg/mL) with immediate use or storage at -20°C for short-term (APExBIO). In animal studies, oral dosing at 10 mg/kg yields a C_max of 0.8 μg/mL and a bioavailability of 25%. Co-administration with ritonavir is recommended for maximal plasma exposure. For resistance profiling, Lopinavir is benchmarked against wild-type, Val82 mutant, and multi-mutant HIV-1 proteases. It is essential to include serum in assays to model physiological conditions accurately.

Contrast: Previous articles focused primarily on HIV; this article contextualizes Lopinavir's cross-pathogen potential and expands on its resistance and pharmacokinetic properties.

Conclusion & Outlook

Lopinavir remains a gold standard for HIV protease inhibition research, combining picomolar potency, robust serum stability, and activity against resistant strains. Its utility extends to cross-pathogen antiviral studies, as evidenced by activity against MERS-CoV in vitro. Researchers should use freshly prepared solutions and appropriate co-administration protocols to maximize efficacy. As resistance landscapes evolve, Lopinavir’s defined benchmarks and APExBIO’s quality-controlled supply enable reproducible, high-impact antiviral research. For more information or to order, see the Lopinavir A8204 product page.